Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, Mallinkrodt LLC, and Takeda Oncology.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASH: Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds

ASH: Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds


Friday, November 30, 2018
1:30PM-4:30PM
Lunch and registration: 12:30 PM – 1:30 PM

Manchester Grand Hyatt San Diego
Lunch Room: Grand Hall D, Lobby Level
Symposia Room: Grand Hall D, Lobby Level
1 Market Place
San Diego, CA 92101

Overview:

A great deal of progress has been made in the understanding of the mechanistic underpinnings of acute and chronic graft-versus host disease (GvHD). It is important for you to be able to apply up-to-the-minute clinical data related to recent approvals and late-stage compounds to maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion. To help you optimize the management of your patients at risk of developing acute or chronic GvHD, this educational curriculum includes the most recent clinical advances in novel diagnostic, therapeutic, and patient counseling strategies that will potentially impact management of patients with acute and chronic GvHD.

This symposium is designed to educate audiences in an innovative, engaging format, and will include a mix of didactic lecture, case studies that reflect challenges faced by community healthcare professionals, panel discussion, and Q&A. The program is designed to be fast-paced and highly interactive between faculty and audience. Case studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions, and to provide the audience an opportunity to reflect on best practices and their own clinical decisions for higher educational engagement. This program will arm you with the most up-to-date information for personalizing care for your patients at risk of developing acute or chronic GvHD.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with GvHD. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of GvHD are also invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the pathogenesis of acute and chronic GvHD and guidelines to assess, stage, and manage patients with these conditions
  • Outline preventive strategies to deter the development of acute GvHD and chronic GvHD in patients undergoing hematopoietic stem cell transplantation
  • Evaluate the clinical benefits and safety of novel and emerging agents and regimens to decrease risk as well as treat acute and chronic GvHD
  • Discuss novel biomarkers that can facilitate the identification of acute and chronic GvHD and the probability of treatment response

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, Mallinkrodt LLC, and Takeda Oncology.

Activity Chair

Corey Cutler, MD, MPH, FRCP(C)
Associate Professor of Medicine
Harvard Medical School
Division of Hematologic Oncology<> Dana-Farber Cancer Institute
Boston, MA







Become a Member

Forgot Password?
Filter By